Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience

• Published in: JCO global oncology 2022-11, Vol.8 (8), p.e2200032
• Main Authors: Meena, Rajendra Kumar, Syed, Nisar Ahmad, Sheikh, Zahoor Ahmad, Guru, Faisal Rashid, Mir, Mohmad Hussain, Banday, Saquib Zaffar, Mp, Arun Krishnan, Parveen, Shaheena, Dar, Nazir Ahmad, Bhat, Gull Mohammad
• Format: Article
• Language: English
• Subjects: Carcinoma, Ovarian Epithelial - pathology; Carcinoma, Ovarian Epithelial - therapy; Female; Humans; Middle Aged; Neoplasm Staging; ORIGINAL REPORTS; Ovarian Neoplasms - epidemiology; Ovarian Neoplasms - therapy; Retrospective Studies; Treatment Outcome
• ISSN: 2687-8941; 2687-8941
• DOI: 10.1200/GO.22.00032

Ovarian cancer (OC) is ranked as the third most common gynecologic cancer in various Indian cancer registries. In India, OC is seen in the younger age group, with a median age < 55 years being reported by most of the studies. The majority of patients are diagnosed in advanced stage (70%-80%), where the long-term (10-year) survival rate is poor, estimated at 15%-30%. The aim of this study was to evaluate clinical epidemiology, treatment patterns, and survival outcomes in patients with epithelial OC. This was a retrospective analysis of patients with epithelial OC who were treated at Sher-i-Kashmir Institute of Medical Sciences, Srinagar, over a period of 9 years, from January 2010 to December 2018. OC constituted 2.94% of all cancers registered. Epithelial OC constituted 88.4% of all OCs, with a median age 50 years. More than two third of patients belonged to rural background and the majority (76.9%) of the patients were in stage III or IV at the time of diagnosis. The main presenting symptoms were abdominal distension/bloating (46.5%) and gastrointestinal disturbances (35.2%). The most common histologic types were serous (65.9%) followed by mucinous carcinoma (15%). Median overall survival for the whole study cohort was 30 months (95% CI, 28.0 to 31.9). Median overall survival for stage I, II, III, and IV was 72, 60, 30, and 20 months, respectively. Most of the patients presented in advanced stage of the disease and have poor outcome. Delay in diagnosis and improper management before registering in tertiary cancer center and lack of tertiary care facilities are the root causes of poor outcomes. The general population and primary care physicians need to be made aware of OC symptoms.